Where Do The EU & The US Stand On Decentralized Clinical Trials?
Executive Summary
Guidance on regulatory and data protection considerations for decentralized clinical trials varies widely between the EU and the US. Trial sponsors need to pay particular attention to issues such as missing data, informed consent and data collection, say lawyers from Sidley Austin.
You may also be interested in...
EMA Finalizes Key Guideline On Use Of Digital Tech To Capture Electronic Trial Data
The European Medicines Agency has published a keenly awaited guidance document on how to use computerized systems in clinical trials while ensuring data integrity and patient rights.
EU Aims To Drive Uptake In Decentralized Clinical Trials With Harmonized Guide
The highly anticipated pan-EU recommendation paper on decentralized clinical trials explains the factors that sponsors should consider when designing and implementing such trials.
ICH Drafts Modernized Principles For E6 Good Clinical Practice Guide
As part of efforts to “renovate” its good clinical practice (GCP) framework, the International Council for Harmonisation has framed new overarching GCP principles that can be applied to diverse trial types and data sources.